LaunchWorks CDMO Approved for Viral Transport Media

LaunchWorks CDMO has been approved to manufacture and distribute Viral Transport Media, in accordance with Section IV.B of the FDA’s COVID-19 Transport Media Policy. The company’s Viral Transport Media is available in the form of bulk tubes, large volume containers and a specimen kit, which will include a tube of sterile LaunchWorks VTM, a biohazard bag and an absorbent bag. Additional options include Nylon-flocked NP swab, Barcode or QP-coded labels, patient card, and a UN 3373 return box.

The Viral Transport Media is a new addition to the LaunchWorks suite of products and service offerings. As an FDA-registered ISO 13485 certified company, LaunchWorks is a division of Integreon Global, which has supported LaunchWorks’ expansion in molecular diagnostics with the additions of new service offerings, including embarking on an automation program designed to help its customers be more competitive. Recently, a significant portion of the company’s efforts have involved the response to the COVID-19 crisis, and the development of Viral Transfer Media is a valuable addition.

“We’re grateful to contribute to the fight against the pandemic, and to add this important component to our product portfolio,” says Jeff Kelly, General Manager of LaunchWorks CDMO. “Our team has worked hard to bring this product to market, and the addition brings us one step closer to offering an end-to-end solution for our customers supporting the fight against COVID-19.